Anlon Healthcare
add_icon

Anlon Healthcare

157.42
-8.29
(-5.00%)
Market Cap
₹836.71 Cr
PE Ratio
39.94
Volume
2,35,991.00
Day High - Low
₹165.50 - ₹157.42
52W High-Low
₹172.75 - ₹90.78
ann
There are new updates from the company2 hours ago
Viewcross
right
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
836.71 Cr
EPS
6.37
PB Ratio
4.07
Book Value
37.90
EBITDA
32.40
Dividend Yield
0.00 %
Industry
Healthcare
ROE Growth %
-
Debt to Equity
1.46
Forecast For
Actual

Company News

View All News
Caret
positive
Anlon Healthcare Limited entered into a Share Purchase Agreement to acquire 67.48% shareholding in Apiqo Organics Private Limited for Rs 5.40 crore, making it a subsidiary. The acquisition enhances vertical integration and adds 700-800 MT annual manufacturing capacity for pharmaceutical intermediates, strengthening the company's position as a reliable partner for global pharmaceutical companies.
positive
Anlon Healthcare Acquires Majority Stake in Bizotic Lifescience for ₹38 Million3 days ago
Anlon Healthcare is acquiring a 56.67% stake in Bizotic Lifescience for ₹38 million rupees. This acquisition will give Anlon Healthcare majority control over Bizotic Lifescience's operations and business.
positive
Anlon Healthcare delivered exceptional quarterly results with total income rising 116% to INR 52.32 crore and PAT jumping nearly 4x to INR 9.32 crore, driven by strong operating leverage and improved business mix. The company is planning a 700 metric ton greenfield expansion and exploring inorganic acquisitions to meet growing demand from regulated markets, targeting 30% revenue CAGR over the next three years.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,799.50
#1 4,31,760.33
40.68
#1 54,729.00
9.71
#1 10,980
2.89
68.38
6,417.50
1,70,364.46
69.05
9,712.00
18.67
2,191
35.10
46.14
3,728.00
1,26,172.46
58.80
11,539.40
6.99
1,911
30.46
55.10
1,516.60
1,22,503.98
22.73
28,409.50
7.12
5,291
3.71
47.90
1,275.20
1,06,429.95
#1 18.15
33,741.20
16.73
5,725
-0.38
57.71
2,082.70
95,128.26
21.34
22,909.50
13.74
3,306
#1 72.75
64.98
942.70
94,857.68
18.56
23,511.00
18.55
4,615
34.60
41.55
2,216.40
91,483.79
52.05
12,744.20
#1 20.90
2,007
-21.05
35.57
1,215.20
70,579.01
20.70
32,345.60
9.43
3,484
3.81
60.02
5,638.50
67,416.73
28.29
13,458.30
3.70
2,216
10.98
46.61
Growth Rate
Revenue Growth
80.66 %
Net Income Growth
111.34 %
Cash Flow Change
-598.14 %
ROE
-44.45 %
ROCE
43.74 %
EBITDA Margin (Avg.)
15.12 %

Yearly Financial Results

Annual Financials
2021
2022
2023
2024
2025
TTM
Revenue
16
58
113
67
121
148
Expenses
21
52
101
51
88
113
EBITDA
-5
6
13
16
32
35
Operating Profit %
-33 %
9 %
11 %
23 %
27 %
24 %
Depreciation
2
2
2
2
2
2
Interest
3
4
4
4
4
4
Profit Before Tax
-10
-0
7
10
27
29
Tax
0
0
1
0
6
9
Net Profit
-10
-0
6
10
21
20
EPS in ₹
-8.53
-0.09
4.85
6.68
6.37
6.40

Balance Sheet

Balance Sheet
2021
2022
2023
2024
2025
Total Assets
71
85
112
128
181
Fixed Assets
29
27
26
27
23
Current Assets
40
58
86
101
159
Capital Work in Progress
0
0
0
0
0
Investments
0
2
4
1
1
Other Assets
43
56
82
100
158
Total Liabilities
71
85
112
128
181
Current Liabilities
31
29
44
50
60
Non Current Liabilities
38
55
61
57
41
Total Equity
2
2
7
21
80
Reserve & Surplus
-10
-10
-5
5
41
Share Capital
12
12
12
16
40

Cash Flow

Cash Flow
2021
2022
2023
2024
2025
Net Cash Flow
-2
1
-1
2
-1
Investing Activities
-3
-0
-0
-3
3
Operating Activities
-15
-2
-3
-3
-23
Financing Activities
16
3
2
8
19

Share Holding

% Holding
Oct 2024
Apr 2025
Jun 2025
Aug 2025
Sept 2025
Promoter
70.26 %
70.26 %
52.68 %
70.26 %
52.68 %
FIIs
0.00 %
0.00 %
14.42 %
0.00 %
0.00 %
DIIs
0.00 %
0.00 %
4.35 %
0.00 %
2.83 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
0.00 %
14.64 %
0.00 %
20.73 %
Others
29.74 %
29.74 %
13.92 %
29.74 %
23.75 %
No of Share Holders
109
131
9,125
135
9,126

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
11 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
11 Nov 2025 139.10 142.50

Announcements

Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements2 hours ago
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements3 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation6 days ago
Announcement under Regulation 30 (LODR)-Earnings Call Transcript7 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 19, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationNov 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 13, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportNov 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 12, 2025
Statement Of Deviation & VariationNov 11, 2025
Financial Result For The Quarter And Half Year Ended September 30 2025.Nov 11, 2025
Board Meeting Outcome for To Consider And Approve The Financial Result For The Quarter And Half Year Ended September 30 2025Nov 11, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Nov 07, 2025
Board Meeting Intimation for Consider And Approve The Financial Results For The Quarter And Half Year Ended September 30 2025.Nov 06, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Nov 06, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On Thursday October 16 2025Oct 16, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 14, 2025
Board Meeting Intimation for Consider General Business Matter.Oct 13, 2025
Closure of Trading WindowSep 29, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 29, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On Saturday September 27 2025Sep 27, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 27, 2025
Board Meeting Intimation for Consider And Approve Proposal For Purchase Of Immovable Property.Sep 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 23, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 22, 2025
Announcement As Per Regulation 30 Of SEBI LODR Regulations 2015 For Development Of New Product.Sep 20, 2025
Clarification On Price Movement Regarding Letter Received From L/SURV/ONL/PV/AJ/ 2025-2026 / 3092Sep 18, 2025
Clarification sought from Anlon Healthcare LtdSep 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 17, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 15, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 13, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 10, 2025
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Sep 09, 2025
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Sep 09, 2025
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Sep 08, 2025
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Sep 04, 2025
Listing of Equity Shares of Anlon Healthcare LtdSep 03, 2025

Technical Indicators